65,437 trials
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 — -0.033; 0.090 Liter — p=<0.001
Respiratory Illness
Primary: Infants Living in Smoke-free Environments. — 65; 64 participants
Urinary Tract Infection · Infection Due to ESBL Bacteria · Environmental Contamination of ESBL
Primary: Treatment Failure — 23; 101 Treatment success
Basal Cell Carcinoma
Primary: Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell…
Coronary Artery Disease
Primary: Safety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse Events — 10; 10; 0; 2 participants
Renal Transplant Rejection · Transplants and Implants
Primary: Composite End Point of Acute Rejection, Graft Loss or Patient Death — 1; 1; 0; 0 participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.35; -1.22 percentage of glycosylated haemoglobin
Stress
Primary: Number of Participants Reporting Pediatric Symptoms as Assessed by the Pediatric Symptom Checklist-17 (PSC-17) — 3; 2; 4; 3 participants
Menopause
Primary: Change of Average 24 h Hot Flash Score From Baseline — -2.29; -0.71; -0.78; -0.71 Scores on a scale
Obesity · Obesity, Morbid · Pregnancy
Primary: Anti Xa Level — 0.14; 0.30 IU/mL
Constipation
Primary: the Change in Mean Weekly CSBMs During Weeks 1-8 Since Treatment — 1.72; 0.82 number of times — p=<0.001
Rheumatoid Arthritis
Primary: Percentage of Participants on Tocilizumab Treatment at Month 6 — 76.6 percentage of participants
Psoriasis
Primary: Mean Gross Change in Psoriasis Area and Severity Index (PASI) Scores From Baseline to the End of 6 Months — -2.15; -1.69 units on a scale
Low Back Pain
Primary: Numeric Pain Rating Score — 7.9; 8.1; 4.9; 3.4 units on a scale — p=<0.001
Neoplasms, Pulmonary · Thoracic Diseases
Primary: Surgical Grading for Lung Isolation — 12; 13; 15; 14 participants